High expression levels of HMGA1 mRNA in lung tumors and relatively low expression levels in non-cancerous tissue of the lung allow us to assume that such therapies would have clinical advantages in lung cancer because of presumed low toxicity toward healthy cells. This evidence concerns the gene HMGA1 and lung carcinoma.